KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Amortization (2019 - 2020)

Historic Amortization for Xenon Pharmaceuticals (XENE) over the last 2 years, with Q1 2020 value amounting to $15.1 million.

  • Xenon Pharmaceuticals' Amortization rose 2851.68% to $15.1 million in Q1 2020 from the same period last year, while for Dec 2019 it was $144.9 million, marking a year-over-year change of. This contributed to the annual value of $144.9 million for FY2019, which is N/A changed from last year.
  • According to the latest figures from Q1 2020, Xenon Pharmaceuticals' Amortization is $15.1 million, which was up 2851.68% from $144.9 million recorded in Q4 2019.
  • In the past 5 years, Xenon Pharmaceuticals' Amortization registered a high of $144.9 million during Q4 2019, and its lowest value of $11.8 million during Q1 2019.